LONDON, GREATER LONDON, UNITED KINGDOM, September 11, 2025 / EINPresswire.com / -- What Is The Expected Cagr For The High Purity Alkylating Agents Market Through 2025?

LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both ...

Lantern Pharma (LTRN) announced the completion of its Phase 1a clinical trial for LP-184. The trial met all primary endpoints, demonstrating a ...

Opportunities for guanine compounds lie in their use for antiviral, anticancer, and enzyme inhibitor therapies. Innovations in synthetic biology and high-throughput screening enhance development, ...

Newer targeted therapies, including BTKis and venetoclax, improve survival in CLL patients aged 80 and older, despite their underrepresentation in pivotal trials. Venetoclax-treated patients showed a ...